Tower Research Capital (TRC)’s Indaptus Therapeutics INDP Stock Holding History
Bought
Maintained
Sold
Other funds holding INDP
HF
SS
Tower Research Capital (TRC)'s INDP Position: Q2 2026 in Review
Tower Research Capital (TRC) sold out of Indaptus Therapeutics (INDP) in Q2 2026, closing a stake of 1,890 shares — an estimated $3.44K sold.
Tower Research Capital (TRC) first reported a position in INDP in Q2 2019 and held it in 17 quarters. The position peaked at $26K in Q2 2019. 9 funds tracked by Wall St. Rank hold INDP as of Q2 2026.
- Tower Research Capital (TRC) reported no remaining Indaptus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,890 Indaptus Therapeutics shares in Q2 2026, an estimated $3.44K.
- Tower Research Capital (TRC) first reported a position in Indaptus Therapeutics in Q2 2019 and held it in 17 quarters.
- Tower Research Capital (TRC)'s Indaptus Therapeutics position peaked at $26K in Q2 2019.
- 9 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.